Drugs / Aitua Combination Antibody
Aitua Combination Antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07432594 | Mar 2026 → May 2027 expected | fallopian tube cancer, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aitua Combination Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07432594 ↗ |
| Known as | Aitua | “Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer” NCT07432594 ↗ |
| Known as | Aitua Combo Ab | “Nab-Paclitaxel + Carboplatin + Aitua Combo Ab” NCT07432594 ↗ |
| Route | Intravenous | “Administered via intravenous infusion at a dose of 5 mg/kg on Day 1 of each 3-week cycle.” NCT07432594 ↗ |